CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- 4 Planned sale CLO & Secretary sold 5,000 shares at an average $201.24 ($1,006,224)
- 144 Insider Sale of Securities
- 4 Open-market sale Director sold 2,161 shares at $200.76 ($433,842)
- 4 Grant or award Chief Financial Officer acquired 4,933 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 10,495 shares (grant or award)
- 4 Grant or award CLO & Secretary acquired 4,513 shares (grant or award)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale Director sold 1,000 shares at $207.87 ($207,873)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Financial Officer sold 3,057 shares at $225.00 ($687,825)
- 144 Insider Sale of Securities
- 4 Planned sale CLO & Secretary sold 5,000 shares at an average $206.35 ($1,031,770)
- 4 Planned sale Chief Financial Officer sold 13,423 shares at an average $205.83 ($2,762,822)
- 144 Insider Sale of Securities
- 4 Open-market sale Director sold 2,034 shares at $201.50 ($409,851)
- 4 Planned sale Director sold 467 shares at an average $200.50 ($93,632)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- S-3ASR Offering Registration Statement
Page 5 of 115 · 2,300 filings